CSIMarket Company Name, Ticker, Customers, else..
 
Krystal Biotech Inc   (NASDAQ: KRYS)
Other Ticker:  
 
 
Price: $173.4000 $-13.72 -7.332%
Day's High: $193.07 Week Perf: -6.4 %
Day's Low: $ 170.00 30 Day Perf: -0.58 %
Volume (M): 478 52 Wk High: $ 219.34
Volume (M$): $ 82,889 52 Wk Avg: $167.47
Open: $191.16 52 Wk Low: $107.50



 Market Capitalization (Millions $) 5,185
 Shares Outstanding (Millions) 30
 Employees 98
 Revenues (TTM) (Millions $) 242
 Net Income (TTM) (Millions $) 52
 Cash Flow (TTM) (Millions $) 1
 Capital Exp. (TTM) (Millions $) 5

Krystal Biotech Inc
Krystal Biotech Inc is a biotechnology company that specializes in developing gene therapy treatments for various skin disorders. The company focuses on leveraging its proprietary skin-targeted gene therapy platform to create highly effective and minimally invasive treatments for diseases such as epidermolysis bullosa and other genetic skin conditions. Krystal Biotech aims to improve the lives of patients through innovative gene therapy solutions and is dedicated to advancing the field of gene therapy for dermatological diseases.


   Company Address: 2100 Wharton Street Pittsburgh 15203 PA
   Company Phone Number: 586-5830   Stock Exchange / Ticker: NASDAQ KRYS


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
CRBU   -8.92%    
DNA   -11.68%    
IMCR   -3.84%    
MRNA   -3.04%    
NVAX        0.78% 
RLAY   -0.74%    
• View Complete Report
   



Clinical Study

Breakthrough in Gene Therapy Initial Clinical Findings from Krystal Biotechs Programs for Alpha-1 Antitrypsin Defici...

Published Thu, Dec 12 2024 1:00 PM UTC

AbstractIn a landmark development for the treatment of Alpha-1 Antitrypsin Deficiency (AATD), Krystal Biotech has announced promising early clinical findings from its innovative gene therapy programs, KB408 and KB407. These findings suggest effective gene delivery and therapeutic protein expression in the lungs of patients suffering from this rare respiratory condition, pot...
Clinical Study

Jeune Aesthetics KB301 Shines in Phase 1, Promises New Standard in Anti-Aging Treatments,

Published Wed, Aug 28 2024 11:00 AM UTC

Jeune Aesthetics Unveils a New Era in Anti-Aging: Phase 1 Breakthrough Results for KB301In an era where the quest for youthfulness and ageless beauty has gained unprecedented momentum, Jeune Aesthetics has unveiled positive interim results for their breakthrough anti-aging treatment, KB301. Examined in a Phase 1 clinical trial, KB301 has shown promising safety and efficacy ...
Clinical Study

Krystal Biotech Reports Strong Q2 2024 Revenue and Promising Advances in Gene Therapy for Ocular Complications ...

Published Mon, Aug 5 2024 12:01 PM UTC

Krystal Biotech s Promising Advances in Gene Therapy: A Closer Look at Recent DevelopmentsIn an exciting update for both the biotechnology and healthcare sectors, Krystal Biotech, Inc. recently announced its financial results for the second quarter of 2024, complemented by significant business updates. Most notably, the company reported impressive net product revenue of $70...
Krystal Biotech Inc

Krystal Biotech Inc. Reports Impressive Financial Results and Breakthrough in Cancer Treatment Research

As a financial journalist for the CSIMarket.com, I am thrilled to report on the recent financial results announced by Krystal Biotech Inc. The commercial-stage biotechnology company declared $45.25 million in revenue for the fiscal first quarter of 2024, showcasing a strong start to the year. Additionally, the company booked a net income of $0.932 million in the same period, a significant improvement compared to a net deficit of $-45.297 million in the corresponding quarter a year ago.
Krystal Biotech's positive financial performance is further complemented by a recent groundbreaking development in the global oncology field. The company, known for its innovative gene therapeutics, has administered the first dose of their novel therapy, inhaled KB707, to a patient in a Phase 1 clinical trial. This trial is focused on treating patients with advanced lung tumors, a crucial step towards revolutionizing oncology treatments and offering hope to individuals battling serious conditions.
Clinical Study

Pioneering Therapeutics: Exploring KB707 in the Battle Against Advanced Lung Cancer

Published Mon, Apr 22 2024 11:01 AM UTC

In a positive turn of events for the global oncology field, Krystal Biotech, a forward-thinking Carnegie Mellon spinoff focused on pioneering gene therapeutics, has announced the administration of the first dose to a patient in a Phase 1 clinical trial of their novel therapy, inhaled KB707. This trial focuses on treating patients with locally advanced or metastatic solid tum...






Krystal Biotech Inc's Segments





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com